<p>In this issue of <i>Acta Physiologica</i>, Kleis-Olsen et al.<span><sup>1</sup></span> investigated the association of postmenopausal hormone replacement therapy (HRT) with skeletal muscle mitochondrial function measured using biopsy samples from human vastus lateralis muscle. They reported that postmenopausal women who received a combination of estradiol and progestin had higher mitochondrial respiratory capacity in the skeletal muscle compared with non-treated postmenopausal women. Since estrogen deficiency due to menopause is associated with skeletal muscle dysfunction characterized by muscle weakness and muscle loss,<span><sup>2</sup></span> it is clinically relevant to examine whether HRT may prevent menopause-related impairment of skeletal muscle energy metabolism.</p><p>Menopause is defined by the permanent cessation of menstruation occurred at an average age around 50 years. It is natural course of reproductive aging for women and the transition into menopause is characterized by a significant reduction in circulating estrogen levels. Menopause may accelerate age-related functional decline with both physiological and psychological symptoms and adversely affect cardiovascular and musculoskeletal health. Because women live longer than men, women are more likely to experience negative changes in skeletal muscle, leading to reduced quality of life with increased morbidity and mortality.<span><sup>3</sup></span></p><p>HRT is a pharmacological therapy that contains ovarian hormones (estrogen with or without progesterone), prescribed to manage menopausal symptoms. Although estrogen alone is enough to treat menopausal symptoms, it may increase the risk of cancer of the uterus (endometrial cancer), and therefore, progesterone is usually added to estrogen to reduce the risk of endometrial cancer back to normal. HRT has multiple health benefits, including reduced risk of cardiovascular diseases and all-cause mortality as well as relief of menopausal symptoms.<span><sup>3</sup></span> Estrogen is considered to be a key regulator of whole-body energy homeostasis.<span><sup>4</sup></span> Compared with other organs, skeletal muscle exhibits higher metabolic flexibility in response to hormone stimulation as well as exercise and environmental factors.<span><sup>5</sup></span> However, the effect of HRT on skeletal muscle mitochondria in postmenopausal women remains fully unclear.</p><p>Previous studies have shown the effects of estrogen on skeletal muscle mitochondria in ovariectomized rodents (animal models of menopause),<span><sup>6, 7</sup></span> but Kleis-Olsen et al. for the first time demonstrated the association of postmenopausal HRT with increased mitochondrial respiratory capacity in the skeletal muscle in human.<span><sup>1</sup></span> Middle-aged postmenopausal women who had received a combination of estradiol and progestin for 3.6 years on average were participated in their cross-sectional study. Compared with matched non-treated postmen
{"title":"Skeletal muscle mitochondria: A potential target for postmenopausal hormone replacement therapy","authors":"Takashi Yokota","doi":"10.1111/apha.14149","DOIUrl":"10.1111/apha.14149","url":null,"abstract":"<p>In this issue of <i>Acta Physiologica</i>, Kleis-Olsen et al.<span><sup>1</sup></span> investigated the association of postmenopausal hormone replacement therapy (HRT) with skeletal muscle mitochondrial function measured using biopsy samples from human vastus lateralis muscle. They reported that postmenopausal women who received a combination of estradiol and progestin had higher mitochondrial respiratory capacity in the skeletal muscle compared with non-treated postmenopausal women. Since estrogen deficiency due to menopause is associated with skeletal muscle dysfunction characterized by muscle weakness and muscle loss,<span><sup>2</sup></span> it is clinically relevant to examine whether HRT may prevent menopause-related impairment of skeletal muscle energy metabolism.</p><p>Menopause is defined by the permanent cessation of menstruation occurred at an average age around 50 years. It is natural course of reproductive aging for women and the transition into menopause is characterized by a significant reduction in circulating estrogen levels. Menopause may accelerate age-related functional decline with both physiological and psychological symptoms and adversely affect cardiovascular and musculoskeletal health. Because women live longer than men, women are more likely to experience negative changes in skeletal muscle, leading to reduced quality of life with increased morbidity and mortality.<span><sup>3</sup></span></p><p>HRT is a pharmacological therapy that contains ovarian hormones (estrogen with or without progesterone), prescribed to manage menopausal symptoms. Although estrogen alone is enough to treat menopausal symptoms, it may increase the risk of cancer of the uterus (endometrial cancer), and therefore, progesterone is usually added to estrogen to reduce the risk of endometrial cancer back to normal. HRT has multiple health benefits, including reduced risk of cardiovascular diseases and all-cause mortality as well as relief of menopausal symptoms.<span><sup>3</sup></span> Estrogen is considered to be a key regulator of whole-body energy homeostasis.<span><sup>4</sup></span> Compared with other organs, skeletal muscle exhibits higher metabolic flexibility in response to hormone stimulation as well as exercise and environmental factors.<span><sup>5</sup></span> However, the effect of HRT on skeletal muscle mitochondria in postmenopausal women remains fully unclear.</p><p>Previous studies have shown the effects of estrogen on skeletal muscle mitochondria in ovariectomized rodents (animal models of menopause),<span><sup>6, 7</sup></span> but Kleis-Olsen et al. for the first time demonstrated the association of postmenopausal HRT with increased mitochondrial respiratory capacity in the skeletal muscle in human.<span><sup>1</sup></span> Middle-aged postmenopausal women who had received a combination of estradiol and progestin for 3.6 years on average were participated in their cross-sectional study. Compared with matched non-treated postmen","PeriodicalId":107,"journal":{"name":"Acta Physiologica","volume":"240 6","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apha.14149","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140613721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}